In the medicinal chemistry for drug discovery market, innovations play a pivotal role, driving advancements in drug development. The dominating segment is precision medicine, where tailored treatments are designed based on an individual's genetic makeup. Innovations such as AI-driven drug discovery and CRISPR technology are revolutionizing how pharmaceuticals are developed. These breakthroughs allow for more targeted therapies, increasing treatment efficacy and reducing side effects. Precision medicine is at the forefront, promising a future where drugs are customized for specific patient needs, and improving overall healthcare outcomes.
Access Full Report @ https://www.databridgemarketresearch.com/de/reports/north-america-medicinal-chemistry-for-drug-discovery-market
Data Bridge Market Research analyses that the North America Medicinal Chemistry for Drug Discovery Market is growing with a CAGR of 14.0% in the forecast period of 2022 to 2029. The market was valued at USD 2,372.67 million in 2021 and is expected to reach USD 6,768.27 million by 2029.
The medicinal chemistry for drug discovery market is driven by the increasing incidence of chronic and infectious diseases, compelling the need for novel and improved medications to address evolving healthcare challenges and improve patient outcomes.
Key Findings of the Study
The aging population is expected to drive the market's growth rate
The medicinal chemistry for drug discovery market is influenced by the world's aging population, which is creating a heightened demand for pharmaceuticals to tackle age-related health concerns. As individuals live longer, there's an increased prevalence of conditions such as cardiovascular diseases, neurodegenerative disorders, and arthritis. This demographic shift is driving research in medicinal chemistry to develop drugs that can effectively address the unique health needs and challenges associated with aging, meeting the growing demand for geriatric healthcare solutions.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014-2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Process (Target Selection, Target Validation, Hit-To-Lead Identification, Lead Optimization, and Candidate Validation), Design (Fragment-Based Variation, Structure-Based Drug Design, Diversity Oriented Synthesis, Chemogenomics, Natural Products, and Others), Drug Type (Small Molecules and Biologics), Therapeutic Area (Oncology, Neurology, Infectious and Immune System Diseases, Cardiovascular Diseases, Digestive System Diseases and Others), End User (Contract Research Organization, Pharmaceuticals and Biotechnology Companies, Academic and Research Institutes and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America
|
|
Market Players Covered
|
Eurofins Scientific (Luxembourg), Covance Inc. (U.S.), WuXi AppTec (China), Charles River (U.S.), Evotec SE (Germany), Piramal Pharma Solutions (India), Pfizer, Inc. (U.S.), Certara, USA (U.S.), Sygnature Discovery Limited (U.K.), Malvern Panalytical Ltd (Parent Company Spectris PLC) (U.K.), Jubilant Biosys Ltd. (A Jubilant Pharmova Limited Company) (India), Taros Chemicals GmbH & Co. KG (Germany), GenScript Biotech Corporation (China), Nereid Therapeutics Inc. (U.S.), BioBlocks, Inc. (U.S.), Charnwood Molecular LTD (U.K.), Domainex (U.K.), Aurigene Pharmaceutical Services Ltd. (a subsidiary of Dr. Reddy’s Laboratories Ltd.) (India), Selvita (Poland), Nanosyn (U.S.), Drug Discovery Alliances Inc. (U.S.)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The North America medicinal chemistry for drug discovery market is segmented into process, design, drug type, therapeutic area, and end user.
- On the basis of process, the North America medicinal chemistry for drug discovery market is segmented into target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation. In 2022, the target selection segment is expected to dominate the medicinal chemistry for drug discovery market. This dominance is attributed to its role in optimizing the research and development process, and efficiently pinpointing potential drug candidates.
In 2022, the target selection segment of the process segment is anticipated to dominate the North America medicinal chemistry for drug discovery market
In 2022, the target selection segment is expected to dominate the medicinal chemistry for drug discovery market. This dominance is attributed to its role in optimizing the research and development process, and efficiently pinpointing potential drug candidates. It contributes to enhanced productivity and effectiveness, driving advancements in pharmaceutical research and development efforts.
- On the basis of design, the North America medicinal chemistry for drug discovery market is segmented into fragment-based variation, structure-based drug design, diversity oriented synthesis, chemogenomics, natural products, and others. In 2022, the fragment-based variation segment is anticipated to lead the medicinal chemistry for drug discovery market. Its prevalence in biotech, pharma, and academic settings enables the identification of numerous compounds crucial for clinical trials and drug development.
In 2022, the fragment-based variation segment of the design segment is anticipated to dominate the North America medicinal chemistry for drug discovery market
In 2022, the fragment-based variation segment is anticipated to lead the medicinal chemistry for drug discovery market. Its prevalence in biotech, pharma, and academic settings enables the identification of numerous compounds crucial for clinical trials and drug development. This segment plays a pivotal role in expediting the launch of new pharmaceutical products.
- On the basis of drug type, the North America medicinal chemistry for drug discovery market is segmented into small molecules and biologics. In 2022, the small molecules segment is poised to lead the medicinal chemistry for drug discovery market. These molecules offer greater specificity, potency, and sustained action, making them preferred choices for drug development, thereby enhancing their market dominance.
- On the basis of therapeutic area, the North America medicinal chemistry for drug discovery market is segmented into oncology, infectious and immune system disease, neurology, cardiovascular disease, digestive system disease, and others. In 2022, the oncology segment is set to dominate the medicinal chemistry for drug discovery market. The rising incidence of cancer and intensified research and development efforts for advanced therapeutic molecules drive the prominence of this segment in the pharmaceutical industry.
- On the basis of end user, the North America medicinal chemistry for drug discovery market is segmented into contract research organization, academic and research institutes, pharmaceutical and biotechnology companies and others. In 2022, the contract research organization (CRO) segment is anticipated to be the dominant force in the medicinal chemistry for drug discovery market. The proliferation of CROs and rising investments in pharmaceutical R&D underscore the pivotal role played by CRO services in advancing drug discovery.
Major Players
Data Bridge Market Research recognizes the following companies as the North America medicinal chemistry for drug discovery market players in North America medicinal chemistry for drug discovery market are Eurofins Scientific (Luxembourg), Covance Inc. (U.S.), WuXi AppTec (China), Charles River (U.S.), Evotec SE (Germany), Piramal Pharma Solutions (India), Pfizer, Inc. (U.S.), Certara, USA (U.S.), Sygnature Discovery Limited (U.K.), Malvern Panalytical Ltd (Parent Company Spectris PLC) (U.K.), Jubilant Biosys Ltd. (A Jubilant Pharmova Limited Company) (India), Taros Chemicals GmbH & Co. KG (Germany), GenScript Biotech Corporation (China).
Market Developments
- In February 2021, Selvita introduced an innovative cell-based phenotypic assay platform for drug discovery. This platform serves as a valuable tool to evaluate the therapeutic potential of new compounds across a spectrum of diseases, including fibrotic and neuroinflammatory conditions. By offering this platform, Selvita expanded its portfolio of drug discovery services, attracting more clients and opportunities. This diversification enhanced the company's revenue streams and solidified its position in the drug discovery industry.
- In August 2020, Piramal Pharma Solutions joined forces with Epirium Bio for an exclusive Integrated Development & Manufacturing Program focused on orphan drugs. This collaboration encompassed various facets, including formulation development, drug substance synthesis, and drug product manufacturing. By expanding its capabilities in this niche area, Piramal Pharma Solutions augmented its existing portfolio in the medicinal chemistry for drug discovery market, strengthening its position as a provider of comprehensive solutions for the development of orphan drug therapies.
Regional Analysis
U.S. dominates North America medicinal chemistry for drug discovery market during the forecast period 2022 - 2029
The U.S. dominates the North America medicinal chemistry for drug discovery market, primarily driven by its proactive research efforts focused on rare diseases and orphan drugs. Moreover, the country's escalating healthcare expenditures have further fueled innovation in drug discovery. These factors combined to position the U.S. as a leader in advancing medicinal chemistry, contributing significantly to the development of novel pharmaceuticals for both rare and common medical conditions.
Canada is expected to dominate North America medicinal chemistry for drug discovery market during the forecast period 2022 - 2029
Canada is expected to dominate the North America medicinal chemistry for drug discovery market, primarily attributed to its expanding clinical trials and research and development initiatives, particularly for chronic diseases. The country's commitment to advancing medical research and healthcare innovation is fostering a favorable environment for drug discovery and development, positioning Canada as a growing hub for addressing chronic health challenges and improving patient outcomes.
For more detailed information about the North America medicinal chemistry for drug discovery market report, click here – https://www.databridgemarketresearch.com/de/reports/north-america-medicinal-chemistry-for-drug-discovery-market
